Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: Role of peroxidases, cytochromes P450, and monoamine oxidases

Drug Metabolism and Disposition

Volumn 32, Issue 1, 2004, Pages 49-57

  Dalvie, Deepak K ^a   O'Connell, Thomas N ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACETYLCYSTEINE; ADENOSINE DIPHOSPHATE; AMINE OXIDASE (FLAVIN CONTAINING); CYANIDE; CYTOCHROME P450; DIHYDROPYRIDINIUM; DIHYDROTHIENOPYRIDINIUM DERIVATIVE; DRUG METABOLITE; GLUTATHIONE; HORSERADISH PEROXIDASE; IMINE; MYELOPEROXIDASE; NEUROTOXIN; PEROXIDASE; PYRIDINIUM DERIVATIVE; TERTIARY AMINE; TETRAHYDROISOQUINOLINE DERIVATIVE; THIENOPYRIDINIUM DERIVATIVE; THIOPHENE DERIVATIVE; TICLOPIDINE; UNCLASSIFIED DRUG;

ARTICLE; BACULOVIRUS; CHEMICAL STRUCTURE; DEALKYLATION; DRUG METABOLISM; ELECTRON TRANSPORT; ENZYME REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; NEUROTOXICITY; OXIDATION; OXIDATION KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; STRUCTURE ANALYSIS; TANDEM MASS SPECTROMETRY; THROMBOCYTE AGGREGATION;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; HORSERADISH PEROXIDASE; HUMANS; INSECTS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICROSOMES, LIVER; MONOAMINE OXIDASE; OXIDATION-REDUCTION; PEROXIDASES; PLATELET AGGREGATION INHIBITORS; PYRIDINIUM COMPOUNDS; THIOPHENES; TICLOPIDINE;

ARMORACIA RUSTICANA; GYMNOMYZA SAMOENSIS; UNIDENTIFIED BACULOVIRUS;

EID: 1642498326     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.32.1.49     Document Type: Article

References (40)

1. + induced oxygen radical formation with mitochondrial enzymes. Free Radic Biol Med 15:181-186.
2. Castagnoli N Jr, Rimoldi JM, Bloomquist J, and Castagnoli KP (1997) Potential metabolic bioactivation pathways involving cyclic tertiary amines and azaarenes. Chem Res Toxicol 10:924-940.
3. Desager JP (1994) Clinical pharmacokinetics of ticlopidine. Clin Pharmacokinet 26:347-355.
4. Ferrer F, De Arriba F, Moraleda JM, and Vicente V (1998) Aplastic anemia induced by ticlopidine after placement of coronary artery stents: therapeutic role of granulocyte colony stimulating factor. Clin Drug Investig 15:261-262.
5. Fraire CP (1984) Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function. Agents Action (Suppl) 15:68-75.
6. Gessner W, Brossi A, Shen RS, and Abell CW (1985) Further insight into the mode of action of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). FEBS Lett 183:345-348.
7. Grieco A, Vecchio FM, Greco AV, and Gasbarrini G (1998) Cholestatic hepatitis due to ticlopidine: clinical and histological recovery after drug withdrawal. Case report and review of the literature. Eur J Gastroenterol Hepatol 10:713-715.
8. Guengerich FP, Okazaki O, Seto Y, and Macdonald TL (1995) Radical cation intermediates in N-dealkylation reactions. Xenobiotica 25:689-709.
9. Ha-Duong N-T, Dijols S, Macherey AC, Dansette PM, and Mansuy D (2001a) Inhibition by ticlopidine and its derivatives of human liver cytochrome P450. Mechanism-based inactivation of CYP2C19 by ticlopidine, in Biological Reactive Intermediates VI: Chemical and Biological Mechanisms in Susceptibility to and Prevention of Environmental Diseases (Dansette PM, Snyder R, Delaforge M, Gibson GG, Greim H, Jollow DJ, Monks TJ, and Sipes IG eds) pp 145-148. Kluwer Academic/Plenum Publishers, New York.
10. Ha-Duong N-T, Dijols S, Macherey A-C, Goldstein JC, Dansette PM, and Mansuy D (2001b) Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 40:12112-12122.
11. Igarashi K, Kasuya F, Fukumi M, Usuki E, and Castagnoli N Jr (1995) Studies on the conversion of haloperidol (HP): the role of CYP3A4 in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following i. p. administration of HP. Life Sci 57:2439-2446.
12. Igarashi K, Shibata C, Kasuya F, and Castagnoli N Jr (2000) Involvement of heme and peroxide complex on the conversion of haloperidol and its dehydrated product HPTP to a neurotoxic pyridinium metabolite. Proceedings of the 6th International ISSX Meeting. Drug Metab Rev 33:59.
13. Iverson S, Zahid N, and Uetrecht JP (2002) Predicting drug-induced agranulocytosis: characterizing neutrophil generated metabolites of a model compound, DMP 406 and assessing the relevance of an in vitro apoptosis assay for identifying drugs that may cause agranulocytosis. Chem-Biol Interact 142:175-199.
14. Kam PCA and Nethery CM (2003) The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia 58:28-35.
15. Ko J-W, Desta Z, Soukhova NV, Tracy T, and Flockhart DA (2000) In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP 2C19 and 2D6. Br J Clin Pharmacol 49:343-351.
16. Lesesve JF, Callat MP, Lenormand B, Monconduit M, Noblet C, Moore N, Caron F, Humbert G, Stamatoullas A, and Tilly H (1994) Hematological toxicity of ticlopidine. Am J Hematol 47:149-150.
17. Liu ZC and Uetrecht JP (2000) Metabolism of ticlopidine by activated neutrophils: implications for ticlopidine-induced agranulocytosis. Drug Metab Dispos 28:726-730.
18. Love BB, Biller J, and Gent M (1998) Adverse hematological effects of ticlopidine. Prevention, recognition and management. Drug Saf 19:89-98.
19. Maffrand J-P and Biogegrain R (1979) New synthesis of thieno[3,2-c] pyridines. Heterocycles 12:1479-1482.
20. Maret G, Testa B, Jenner P, El-Tayar N, and Carrupt P-A (1990) The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism. Drug Metab Rev 22:291-332.
21. Masuda M, Suzuki T, Friesen MD, Ravanat JL, Cadet J, Pignatelli B, Nishino H, and Ohshima H (2001) Chlorination of guanosine and other nucleosides by hypochlorous acid and myeloperoxidase of activated human neutrophils. Catalysis by nicotine and trimethylamine. J Biol Chem 276:40486-40496.
22. Mataix R, Ojeda E, Perez MC, and Jimenez S (1992) Ticlopidine and severe aplastic anaemia. Br J Haematol 81:459-460.
23. Muzkat M, Shapira MY, Sviri S, Linton DM, and Caraco Y (1998) Ticlopidine-induced thrombotic thrombocytopenic purpura. Pharmacotherapy 18:1352-1355.
24. Naoi M, Maruyama W, Niwa T, and Nagatsu T (1994) Novel toxins and Parkinson's disease: N-methylation and oxidation as metabolic bioactivation of neurotoxin. J Neural Transm Suppl 41:197-205.
25. Naoi M, Matsuura S, and Parez H (1989) Oxidation of N-methyl-1,2.3-4-tetrahydroisoquinoline into the N-methylisoquinolinium ion by monoamine oxidase. J Neurochem 52:653-655.
26. Noble S and Goa KL (1996) Ticlopidine: a review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischemia and stroke. Drugs Aging 8:214-232.
27. Offen CP, Frearson MJ, Wilson K, and Burnett D (1985) 4,5-Dimethylthiazole-N-oxide-S-oxide: a metabolite of chloromethiazole in man. Xenobiotica 15:503-511.
28. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
29. Ono K, Kurohara K, Yoshihara M, Shimamoto Y, and Yamaguchi M (1991) Agranulocytosis caused by ticlopidine and its mechanism. Am J Hematol 37:166-175.
30. Perez-Balsa A, De Arce A, Castiella A, Lopez P, and Masso JF (1998) Hepatotoxicity due to ticlopidine. Ann Pharmacother 32:1250-1251.
31. +, the monoamine oxidase catalyzed oxidation product of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Med Chem 28:1432-1436.
32. Sayre LM, Arora PK, Feke SC, and Urbach FL (1986) Mechanism of induction of Parkinson's disease by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Chemical and electrochemical characterization of a geminal-dimethyl-blocked analog of a postulated toxic metabolite, J Am Chem Soc 108:2464-2466.
33. Shaffer CL, Morton MD, and Hanzlik RP (2001) N-Dealkylation of an N-cyclopropylamine by horseradish peroxidase. Fate of the cyclopropyl group. J Am Chem Soc 123:8502-8508.
34. Sono M, Roach MP, Coulter ED, and Dawson JH (1996) Heme-containing oxygenases. Chem Rev 96:2841-2887,
35. Steinhubl SR, Tan WA, Foody JM, and Topol EJ (1999) Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. J Am Med Assoc 281:806-810.
36. Tuong A, Bouyssou A, Paret J, and Cuong TG (1981) Metabolism of ticlopidine in rats: identification and quantitative determination of some of its metabolites in plasma, urine and bile. Eur J Drug Metab Pharmacokinet 6:91-98.
37. Usuki E, Pearce R, Parkinson A, and Castagnoli N Jr (1996) Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes. Chem Res Toxicol 9:800-806.
38. Yoshihara S and Ohta S (1998) Involvement of hepatic aldehyde oxidase in conversion of 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+) to 1-methyl-4-phenyl-5,6-dihydro-2-pyridone. Arch Biochem Biophysics 360:93-98.
39. Youngster SK, Sonsalla PK, and Heikkila RE (1987) Evaluation of biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 48:929-934.
40. Zeolla MM and Carson JJ (1999) Successful use of clopidrogel for cerebrovascular accident in a patient with suspected ticlopidine-induced hepatotoxicity. Ann Pharmacother 33:939-941.